AskBio Inc
Clinical trials sponsored by AskBio Inc, explained in plain language.
A gene therapy company, subsidiary of Bayer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy injection aims to repair failing hearts Results expected Oct 2026 (estimated)
-
One-Time gene therapy could change pompe disease treatment
Disease control Recruiting nowThis study tests a single intravenous dose of a gene therapy called AB-1009 in 12 adults with late-onset Pompe disease. Participants must have been on enzyme replacement therapy for at least 6 months. The main goal is to check safety and side effects, while also seeing if the tre…
Phase 1/2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Gene therapy trial hopes to ease Parkinson's symptoms
Disease control Recruiting nowThis Phase 2 study tests whether a single dose of AAV2-GDNF gene therapy, delivered directly into the brain, can improve motor function in adults with moderate Parkinson's disease. About 127 participants will receive either the gene therapy or a sham surgery. The main goal is to …
Phase 2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC